Compare Mattel Inc (MAT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Novartis AG — how do they compare? Mattel Inc trades at $17.09 (market cap $4.74B), while Novartis AG trades at $143.44 (market cap $268.57B). The key difference: Novartis AG is far larger — about 56.7× Mattel Inc's market cap, and Novartis AG pays a 3.31% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Novartis AG for 82 Days on average.
| MAT | NVS | |
|---|---|---|
Market Cap | $4.74B | $268.57B |
Volume | 11,809,722 | 1,532,573 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $168.62 |
52-Week Low | $12.66 | $121.80 |
Typical Hold Time | 97 Days | 82 Days |
Enterprise Value | $6.96B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.37, up 2.76% on the day, with a bullish technical signal and strong profitability metrics including a 20.5% ROE and 7.78% net margin. Recent news highlights takeover interest from Authentic Brands Group and a CEO transition to Roger Lynch. Cash flow turned negative in 2025 at -$145M, but revenue remains stable around $5.3B.
The stock presents a mixed outlook: analyst consensus is a Buy with a $15.00 price target, but recent earnings misses and negative cash flow pose risks. Upside is supported by takeover speculation and solid brand portfolio, while execution under new leadership and Barbie sales trends are key watchpoints.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
